Magnetar Financial’s Alaunos Therapeutics TCRT Stock Holding History

Magnetar Financial’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-220	Closed	-$81K	–	572
2020 Q1	$81K	Buy	+220	New	+$114K	﹤0.01%	445

Other funds holding TCRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Magnetar Financial's TCRT Position: Q2 2020 in Review

Magnetar Financial sold out of Alaunos Therapeutics (TCRT) in Q2 2020, closing a stake of 220 shares — an estimated $81K sold.

Magnetar Financial first reported a position in TCRT in Q1 2020 and held it in 1 quarter. The position peaked at $81K in Q1 2020. 146 funds tracked by Wall St. Rank hold TCRT as of Q2 2020.

Magnetar Financial reported no remaining Alaunos Therapeutics position as of Q2 2020 after selling out during the quarter.
Magnetar Financial sold 220 Alaunos Therapeutics shares in Q2 2020, an estimated $81K.
Magnetar Financial first reported a position in Alaunos Therapeutics in Q1 2020 and held it in 1 quarter.
Magnetar Financial's Alaunos Therapeutics position peaked at $81K in Q1 2020.
146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2020.

Based on Magnetar Financial's 13F filing for Q2 2020, filed 14 Aug 2020.